TerminatedNCT02566759

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Medication studyAges 18–55United KingdomSchizophrenia

The study in practice

Understand this study

This study is for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateSeptember 23, 2015

Recruitment status: Terminated
Enrollment listed in the registry: 110
Sponsor: Neurocrine Biosciences
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United Kingdom
Age range: From 18 Years to 55 Years
Official registry ID: NCT02566759
Official title: Show the full official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects

Terminated

London

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Neurocrine Biosciences, a biotech company.

Does this study involve medication?

Yes. The study involves medication, including TAK-831 Oral Suspension, TAK-831 Placebo and TAK-831 Tablet.

Who can participate?

This study is for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.